EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin By Ogkologos - August 18, 2025 166 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed or refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Teacher’s Mental Health Check-In Board Goes Viral For The ‘Beautiful’ Standard... April 11, 2019 How I Navigated the Challenges of 2 Colorectal Cancer Diagnoses As... January 6, 2022 Neoadjuvant Nivolumab Plus Ipilimumab Leads to a Pathological Response in a... June 12, 2024 Acing it: The ambitious early career researchers driving progress in cancer... January 21, 2022 Load more HOT NEWS Single Mom Has To Beg For Rides To Doctor For Son... The OncoLife Survivorship Care Plan: An Educational Tool For Survivors That... EMA Recommends Extension of Indications for Pembrolizumab Piecing together the puzzle: Antibiotics, the microbiome and bowel cancer
